Search clinical trials for: GT201 in combination with PD-1 inhibitors

Total 1746 results

Grit Biotechnology

Recruiting

GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Adult

China
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
Xiaorong Dong

Unknown

Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

NSCLC | Anlotinib | PD-1/L1 Inhibitor
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Sun Yat-sen University

Recruiting

Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer

Colorectal Cancer Metastatic | MSS

China
Peking Union Medical College Hospital

Recruiting

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Recruiting

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

NSCLC Stage IV

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

Osteosarcoma

China
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Tongji Hospital
National Natural Science Foundation of China

Recruiting

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NICCE)

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Cervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Solid Tumors | Endometrial Carcinoma | Urothelial Carcinoma

United States, Spain, Israel, Czechia, Georgia, Italy, Poland, Turkey, Hungary, Ukraine
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS) (BLESS)

Esophageal Cancer

China
Beijing Friendship Hospital

Recruiting

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

Locally Advanced Rectal Cancer

China
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
Shen Lin

Unknown

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Colorectal Cancer | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancer | Targeted Therapy | HER2

China
Aurora Health Care

Recruiting

BurstDR Stimulation for Painful Diabetic Neuropathy

Painful Diabetic Neuropathy

United States
Peking Union Medical College

Not yet recruiting

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Salivary Gland Cancer
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
Akeso

Not yet recruiting

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Sun Yat-sen University

Recruiting

Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma

Peripheral T-cell Lymphoma

China
Second Affiliated Hospital of Nanchang University

Recruiting

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

Immunotherapy | Tislelizumab | Pulmonary Pleomorphic Carcinoma

China
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
Peking University Cancer Hospital & Institute

Recruiting

Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

Melanoma

China
University Hospital, Bordeaux

Recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI)

Metastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

France
Aura Biosciences

Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
Pyrotech Therapeutics, Inc.

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
JSehouli
GlaxoSmithKline

Unknown

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Ovarian Cancer

Germany
LI XIN-XIANG

Not yet recruiting

A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis (Miracle-2)

Advanced Rectal Cancer | Distal Metastasis

China
West China Hospital
Sichuan Provincial People's Hospital; The First People's Hospital of Ziyang; Chengdu... and other collaborators

Not yet recruiting

The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Amanda Dandanell Juul

Recruiting

Navigation Endobronchial Ultrasound (NEBULA)

Lung Cancer

Denmark
Arvinas Androgen Receptor, Inc.

Active, not recruiting

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer Metastatic

Canada, United States, France, United Kingdom
Hutchmed

Recruiting

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Advanced Solid Tumor

China
AC Camargo Cancer Center

Recruiting

Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT) (BISQUIT)

Anal Cancer Squamous Cell

Brazil
Taro Iguchi, MD, PHD
Bayer Yakuhin, Ltd.

Active, not recruiting

The Combination Therapy With Ra-223 and Enzalutamide (CORE-OCU)

Bone Metastases | Castration-resistant Prostate Cancer

Japan
Dong Wang

Not yet recruiting

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)

ESCC

China
Novita Pharmaceuticals, Inc.

Recruiting

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Advanced or Metastatic Solid Tumor Malignancies

United States
Dalian University

Unknown

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Non-small Cell Lung Cancer
The First Affiliated Hospital of Guangdong Pharmaceutical...
Guangzhou Anjie Biomedical Technology Co., Ltd.

Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer

China
Henan Cancer Hospital

Recruiting

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Metastatic Gastroesophageal Junction Adenocarcinoma

China
Ivoclar Vivadent AG

Recruiting

Clinical Evaluation of a New Flowable and a New Sculptable Universal Bulk-fill Composite for Direct Restorative Treatment

Insufficient Dental Filling or Primary Caries (Class I or II Cavities in Premolars or Molars)

Liechtenstein
Tang-Du Hospital

Completed

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Sintilimab and Anlotinib in Combination With Chemotherapy

China
Atrial Fibrillation Network
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Preventicus GmbH; Corsano... and other collaborators

Completed

The Smartphone and Wearable Detected Atrial Arrhythmia in Older Adults Case Finding Study (Smart in OAC - AFNET 9) (Smart in OAC)

Atrial Arrhythmia

Germany, Poland, Spain
University of Otago
oVRcome

Active, not recruiting

oVRcome Self-guided Virtual Reality for Specific Phobias (oVRcome)

Specific Phobia

New Zealand
Imunon

Completed

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall (DIGNITY)

Breast Cancer

United States
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Active, not recruiting

Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients (ACCRUE)

Non-muscle Invasive Bladder Cancer

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Carotid Artery Plaque | Pd-1 Inhibitors

China

3

Subscribe